Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons
Naemeh Pourshafie, Ester Masati, Eric Bunker, Alec R. Nickolls, Parisorn Thepmankorn, Kory Johnson, Xia Feng, Tyler Ekins, Christopher Grunseich, Kenneth H. Fischbeck
Naemeh Pourshafie, Ester Masati, Eric Bunker, Alec R. Nickolls, Parisorn Thepmankorn, Kory Johnson, Xia Feng, Tyler Ekins, Christopher Grunseich, Kenneth H. Fischbeck
View: Text | PDF
Research Article Genetics Neuroscience

Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons

  • Text
  • PDF
Abstract

Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder caused by a polyglutamine expansion in the androgen receptor (AR). Using gene expression analysis and ChIP sequencing, we mapped transcriptional changes in genetically engineered patient stem cell–derived motor neurons. We found that transcriptional dysregulation in SBMA can occur through AR-mediated histone modification. We detected reduced histone acetylation, along with decreased expression of genes encoding compensatory metabolic proteins and reduced substrate availability for mitochondrial function. Furthermore, we found that pyruvate supplementation corrected this deficiency and improved mitochondrial function and SBMA motor neuron viability. We propose that epigenetic dysregulation of metabolic genes contributes to reduced mitochondrial ATP production. Our results show a molecular link between altered epigenetic regulation and mitochondrial metabolism that contributes to neurodegeneration.

Authors

Naemeh Pourshafie, Ester Masati, Eric Bunker, Alec R. Nickolls, Parisorn Thepmankorn, Kory Johnson, Xia Feng, Tyler Ekins, Christopher Grunseich, Kenneth H. Fischbeck

×

Figure 4

Reduced phosphorylation of proteins in the AMPK signaling pathway in SBMA iMNs.

Options: View larger image (or click on image) Download as PowerPoint
Reduced phosphorylation of proteins in the AMPK signaling pathway in SBM...
Heatmaps represents log2 fold changes (average ratio of signal intensity of phosphorylated antibody/average signal intensity of antibody). Signals were detected across 6 replicates of phosphorylation-specific antibodies and their nonphosphorylated pairs. (A) AMPK phosphorylation. (B) mTORC1 signaling and protein synthesis. (C) AMPK-mediated carbohydrate metabolism. (D) AMPK-mediated lipid metabolism. (E) AMPK upstream regulators. N = 3 SBMA, N = 3 control, and N = 3 AR-KO. (F) A simplified schematic of the AMPK signaling summarizing fold changes of SBMA/control relative to AR-KO/control. Proteins with SBMA/control and KO/control fold-change differences more than 1 SD (red) from the mean were identified as having overall increased activation (hyperphosphorylation). Fold-change differences below 1 SD (blue) indicate an overall decreased activity (hypophosphorylation). Fold-change differences within 1 SD of the mean indicates no difference between AR-KO/control and SBMA/control. iMNs were treated with 10 nM DHT.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts